id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S16157 R67051 |
Alsaadi (Valproate) (Epilepsy) (Controls exposed to LTG), 2020 | Minor congenital malformations | 1st trimester | retrospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
0.16 [0.01;4.15] C excluded (control group) |
0/23 1/12 | 1 | 23 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S16154 R67039 |
Alsaadi (Valproate) (Epilepsy) (Controls unexposed sick), 2020 | Minor congenital malformations | 1st trimester | retrospective cohort | unexposed, sick | Adjustment: No | 1.58 [0.03;82.39] C | 0/23 0/36 | 0 | 23 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9299 R32356 |
Dean (Valproate), 2002 | Minor congenital malformations | at least 1st trimester | retrospective cohort | unexposed, sick | Adjustment: No | 7.50 [2.49;22.56] C | 25/47 5/38 | 30 | 47 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9332 R32556 |
Battino (Valproate), 1992 | Minor anomalies | 1st trimester | prospective cohort | unexposed, sick | Adjustment: No | 7.62 [0.38;152.84] C | 6/21 0/9 | 6 | 21 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9352 R32721 |
Robert (Valproate), 1986 | Minor malformations | 1st trimester | retrospective cohort | unexposed, sick | Adjustment: No | 1.94 [0.38;9.97] C | 3/15 4/35 | 7 | 15 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 4 studies | 4.84 [2.06;11.36] | 43 | 106 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Valproate) (Epilepsy) (Controls unexposed sick; 2: Valproate; 3: Valproate; 4: Valproate;
Asymetry test p-value = NaN (by Egger's regression)
not enought points
excluded 16157